BRG01 Receives FDA Approval for Ph 2 Trial for the treatment of relapsed/metastatic EBV-positive NPC August 22, 2024
FAILED TRIAL: FOCUS Ph II Trial of UV1 + Pembrolizumab didn’t improve PFS & OS in Patients with Metastatic or Recurrent Head and Neck Cancer August 13, 2024
FDA Fast Track Designation Granted to Ozuriftamab Vedotin (CAB-ROR2-ADC) for Patients with Recurrent or Metastatic SCCHN August 7, 2024
Ph 2 Plans Announced for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review August 7, 2024
Alignment with FDA on Ph 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer August 7, 2024
BRG01 Enters Ph 2 Clinical Trial For Solid Tumors On Recurrent/Metastatic Nasopharyngeal Carcinoma July 23, 2024
Ph 3 TrilynX study of xevinapant + CRT in patients with unresected LA SCCHN to be discontinued July 1, 2024
Positive Topline Results from TACTI-003 Ph 2b Trial in 1L Head and Neck Cancer announced July 1, 2024
Updated Interim Ph 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic HNSCC reported July 1, 2024
Tisotumab Vedotin Ph 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic HNSCC June 11, 2024
Adaptimmune and Galapagos Collaborate on uza-cel in Head & Neck Cancer and Potential Future Solid Tumor Indications June 4, 2024
VERSATILE-002 Ph 2 Trial Meets Primary Study Endpoints in 1l Recurrent/Metastatic HPV16-Positive Head and Neck Cancer May 15, 2024
Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in interim assessment of Ph 2 GALAXIES Lung-201 May 15, 2024
Ph 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept + Keytruda in Patients with Untreated HPV-Mediated Oropharyngeal Cancer initiated May 7, 2024
Ph 2/3 pivotal trial design and protocol for HB-200 + Keytruda in 1L HPV16+ recurrent or metastatic oropharyngeal squamous cell carcinoma (OPSCC) aligned with FDA feedback May 1, 2024
MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment March 19, 2024
Transgene, NEC, and BostonGene Expand Collaboration for Ph 1/2 Trial of Neoantigen Cancer Vaccine TG4050 March 12, 2024
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Ph 3 Head and Neck Cancer Study February 26, 2024
